CLAIMS

1. A pharmaceutically acceptable acid addition salt of:
   (i) S-pindolol; and
   (ii) an organic acid,
   wherein the organic acid has: a pK_{a1} of greater than or equal to 2.5; and a chemical formula of $C_xH_y(CO_2H)_z$, where x is from 1 to 10, y is from 2 to 20 and z is 1 or 2.

2. A pharmaceutically acceptable acid addition salt according to claim 1, wherein the organic acid is benzoic acid, succinic acid, fumaric acid, malonic acid, glutaric acid, adipic acid, acetic acid, propionic acid, phenylacetic acid, toluic acid or naphthoic acid.

3. A pharmaceutically acceptable acid addition salt according to claim 1 or 2, wherein the pharmaceutically acceptable acid addition salt is crystalline.

4. A pharmaceutically acceptable acid addition salt according to any one of the preceding claims, wherein the pharmaceutically acceptable acid salt is in the form of a solvate.

5. A pharmaceutically acceptable acid addition salt according to any one of the preceding claims, wherein the organic acid is benzoic acid or succinic acid.

6. A pharmaceutically acceptable acid additional salt according to any one of the preceding claims, wherein the organic acid is benzoic acid.

7. A pharmaceutically acceptable acid addition salt according to any one of the preceding claims, wherein the salt is S-pindolol benzoate.

8. A pharmaceutically acceptable acid addition salt according to claim 7, wherein the S-pindolol benzoate is S-pindolol monobenzoate.

9. A pharmaceutically acceptable acid addition salt according to claim 7 or 8, wherein the S-pindolol benzoate is in the form of S-pindolol benzoate crystalline polymorph Pattern 1 having an x-ray powder diffraction pattern comprising peaks at 8.1°, 11.4° and 17.0° ± 0.2° 2θ.

10. A pharmaceutically acceptable acid addition salt according to claim 9, wherein the x-ray powder diffraction pattern further comprises peaks at 5.7°, 12.5° and 18.4° ± 0.2° 2θ.

11. A pharmaceutically acceptable acid addition salt according to claim 7 or 8, wherein the S-pindolol benzoate is in the form of S-pindolol benzoate crystalline polymorph Pattern 2 having an x-ray powder diffraction pattern comprising peaks at 16.9°, 18.9° and 20.1° ± 0.2° 2θ.

12. A pharmaceutically acceptable acid addition salt according to claim 11, wherein the x-ray powder diffraction pattern further comprises peaks at 9.2°, 13.9° and 20.7° ± 0.2° 2θ.

13. A pharmaceutically acceptable acid addition salt according to any one of claims 1 to 5, wherein the salt is S-pindolol succinate.

14. A pharmaceutically acceptable acid addition salt according to claim 13, wherein the S-pindolol succinate is S-pindolol monosuccinate.

15. A pharmaceutically acceptable acid addition salt according to claim 13 or 14, wherein the S-pindolol succinate is in the form of S-pindolol succinate crystalline polymorph Pattern 1 having an x-ray powder diffraction pattern comprising peaks at 13.3°, 16.7° and 19.5° ± 0.2° 2θ.

16. A pharmaceutically acceptable acid addition salt according to claim 15, wherein the x-ray powder diffraction pattern further comprises peaks at 8.3°, 12.2° and 12.8° ± 0.2° 2θ.

17. A composition comprising at least 60 wt% of a pharmaceutically acceptable acid addition salt as defined in any one of the preceding claims relative to the total weight of the composition.

18. A composition according to claim 17, wherein the composition comprises no more than 30 wt% of R-pindolol or a salt thereof relative to the total weight of the composition.

19. A pharmaceutical composition comprising (i) a pharmaceutically acceptable acid addition salt as defined in any one of claims 1 to 16 and (ii) a pharmaceutically acceptable excipient, carrier or diluent.

20. A pharmaceutical composition according to claim 19, wherein the pharmaceutical composition is a tablet.

21. A pharmaceutical composition according to claim 19 or 20, wherein the composition is substantially free of R-pindolol or a salt thereof.

22. A pharmaceutically acceptable acid addition salt as defined in any one of claims 1 to 16 for use in the treatment of the human or animal body.

23. A pharmaceutically acceptable acid addition salt as defined in any one of claims 1 to 16 for use in the treatment or prevention of a disease or condition selected from cachexia, sarcopenia, a neuromuscular disorder, muscle weakness, hypertension, heart failure, atrial fibrillation, heart attack, angina pectoris, glaucoma and anxiety.

24. A pharmaceutically acceptable acid addition salt as defined in claim 23, wherein the disease or condition is cachexia or muscle weakness.

25. A method of treating or preventing a disease or condition selected from cachexia, sarcopenia, a neuromuscular disorder, muscle weakness, hypertension, heart failure, atrial fibrillation, heart attack, angina pectoris, glaucoma and anxiety in an individual, the method comprising administering a therapeutically effective

amount of a pharmaceutically acceptable acid addition salt as defined in any one of claims 1 to 16 to the individual.